Adverse impacts of medicine shortages on patients Europe 2022

Acording to a survey conducted in late 2022, some 72 percent of European countries who reported experiencing medicine shortages in their countries during the last 12 months reported increased co-payments as an adverse impact. This graph shows the adverse impacts of medicine shortages on patients in European countries who reported medicine shortages.

Adverse impacts of medicine shortages on patients in European countries who reported medicine shortages as of 2022

Characteristic	Percentage of respondent countries
Cause distress and inconvenience	93.1%
Interruption of treatments	89.7%
Increased co-payments	72.4%
Sub-optimal treatment/inferior efficacy	58.6%
Medication errors	34.5%
Adverse events/greater toxicity	21.1%
Death	13.8%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

2023

More information

Region

Europe

Survey time period

November 14 to December 31, 2022

Number of respondents

29 PGEU member countries

Supplementary notes

Original question: "In your opinion, how have medicine shortages adversely affected patients in your country? Tick all that apply."
PGEU member countries who participated in the survey include Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Kosovo, Latvia, Luxembourg, Netherlands, North Macedonia, Norway, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Turkey.
Medicine shortage was defined as every (temporary) inability for a community or hospital pharmacy to supply patients with the medicinal product requested as a result of factors beyond their control, requiring the dispensing of an alternative agent or even discontinuation of an ongoing medical therapy.

Citation formats